Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MEDI4736 Combinations in Metastatic Renal Cell Carcinoma

NCT02819596 is registered in ClinicalTrials.gov with Queen Mary University of London as lead sponsor.

NCT NCT02819596
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02819596 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MEDI4736 Combinations in Metastatic Renal Cell Carcinoma
Lead sponsor
Queen Mary University of London
Phase
Phase 2
Overall status
Completed
Start date
May 3, 2016
Completion date
July 17, 2024
Enrollment
69 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

renal clear cell carcinoma, renal papillary cell carcinoma